Status:
ACTIVE_NOT_RECRUITING
ABA-101 in Participants With Progressive Multiple Sclerosis
Lead Sponsor:
Abata Therapeutics
Conditions:
Progressive Multiple Sclerosis
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
This study will test the safety and effects of ABA-101 when given as a single dose to participants with progressive multiple sclerosis. It is the first study of this treatment in humans. After safety...
Eligibility Criteria
Inclusion
- Is ≥18 years old at signing of consent.
- Has a diagnosis of MS per the 2017 revised McDonald criteria.
- Has documented evidence of progression of disability independent of MS relapse activity (clinical or radiographic).
- Expresses the HLA that matches the TCR restriction.
- Presence of a radiographic biomarker of CNS inflammation as identified by MRI.
- Meets Expanded Disability Status Scale (EDSS) criteria.
- Meets the nine-hole peg test (9HPT) criteria.
Exclusion
- Presents with clinical or radiographic evidence of relapse within 24 months prior to or at Screening.
- Is considered by the Investigator to be immunocompromised.
- Current treatment with disease-modifying therapies (DMTs).
Key Trial Info
Start Date :
September 11 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
February 1 2027
Estimated Enrollment :
12 Patients enrolled
Trial Details
Trial ID
NCT06566261
Start Date
September 11 2024
End Date
February 1 2027
Last Update
July 3 2025
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Johns Hopkins University
Baltimore, Maryland, United States, 21287
2
Rutgers, Robert Wood Johnson Medical School
New Brunswick, New Jersey, United States, 08901
3
Cleveland Clinic Mellen Center
Cleveland, Ohio, United States, 44195